Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2174 • 2014 ACR/ARHP Annual Meeting
MicroRNA-146a in Salivary Gland Epithelial Cells Inhibits Co-Stimulatory Molecule CD80 Expression and Increases Autoreactive T Cell Activation in Sjögren’s Syndrome
Adrienne Gauna¹, Jun-O Jin^2,3, Qing Yu², Carol Stewart¹ and Seunghee Cha¹, ¹Oral and Maxillofacial Diagnostic Sciences, University of Florida, Gainesville, FL, ²Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, ³Shanghai Public Health Clinical Center, Fudan University Shanghai Medical College, Shanghai, China
Background/Purpose: Sjögren’s syndrome (SS) causes severe dry mouth and eyes. The presence of immune cell infiltration in the salivary (SG) and lacrimal glands suggests a…
Abstract Number: 520 • 2014 ACR/ARHP Annual Meeting
Genetic Variant and High Levels of CCL11 in Serum Are Associated with the Occurrence of Lymphoma and Disease Activity in Primary Sjögren’s Syndrome Patients (pSS)
Gaetane Nocturne¹, Olivier Fogel², Joanne Nititham³, Kimberly E. Taylor⁴, Philippe Dieude⁵, Jean Jacques Dubost⁶, Anne-Laure Fauchais⁷, Vincent Goëb⁸, Eric Hachulla⁹, Claire Larroche¹⁰, Véronique Le Guern¹¹, Jacques Morel¹², Aleth Perdriger¹³, Xavier Puéchal¹⁴, Stephanie Rist Bouillon¹⁵, Alain Saraux¹⁶, Damien Sène¹⁷, Olivier Vittecoq¹⁸, Lindsey A. Criswell¹⁹, Corinne Miceli-Richard²⁰, Jacques Gottenberg²¹ and Xavier Mariette²², ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³University of California San Francisco, 374 Parnassus Avenue, San Francisco, CA, ⁴Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁶Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁸Rheumatology, Amiens University Hospital, Amiens, France, ⁹Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ¹⁰Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹³Rhumatologie, Rennes, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁵Rhumatologie, Hopital La Source, La Source, France, ¹⁶CHU Brest and EA 2216, UBO, Brest, France, ¹⁷Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁸Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ¹⁹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²⁰Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ²¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²²rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications of pSS. It occurs in 5-10% of the patients. A more accurate…
Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting
Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Alan N. Baer¹, Michelle Petri², David Fiorentino³, Tao Wang⁴, Jungsan Sohn⁴, Antony Rosen¹ and Livia Casciola-Rosen⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…
Abstract Number: 1799 • 2014 ACR/ARHP Annual Meeting
Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25^hiFoxP3⁺regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue?
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Zana Brkic¹, Sandra M.J. Paulissen^1,2, Virgil A. Dalm¹, Paul L. van Daele¹, P. Martin van Hagen¹, Sinead M. Gibney^1,3, Andrew Harkin³, Hemmo A. Drexhage¹, Erik Lubberts^1,2 and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands, ³Trinity College Institute of Neuroscience, Neuropsychopharmacology, Dublin, Ireland
Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO - the…
Abstract Number: 150 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Major Salivary Glands in Primary Sjogren’s Syndrome: Comparison of Two Scoring Systems and Diagnostic Value of Sonoelastography
Xia Zhang¹, Jing He² and Zhanguo Li³, ¹Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, ³Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose Primary Sjogren’s syndrome (pSS) is a chronic systemic autoimmune disease characterized by clinically xerophthalmia and xerostomia. Those standard tests of salivary glands involvement has…
Abstract Number: 2538 • 2014 ACR/ARHP Annual Meeting
Ultrasound-Guided Core Needle Biopsy of the Major Salivary Glands Is a Safe and Useful Diagnostic Tool in the Evaluation of Suspected or Established Sjögren’s Syndrome
Anand Narayan¹, Thomas Grader-Beck², Julius Birnbaum³, Jean Kim⁴, Qing Kay Li⁵, Deborah Belchis⁵, Joel Fradin¹ and Alan N. Baer⁶, ¹Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Ultrasound-guided core needle biopsy (CNB) has greater inherent risks than fine-needle aspiration for the diagnosis of major salivary gland neoplasms, but provides tissue for…
Abstract Number: 1798 • 2014 ACR/ARHP Annual Meeting
Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for the Induction of Sjogren’s Syndrome-like Disease in Mice
Paulina Kaplonek¹, Barbara Szczerba², Nina Wolska¹, Paulina Rybakowska¹, Arkadiusz Klopocki¹, Paromita Dey³, Astrid Rasmussen⁴, Kimberly Hefner⁵, Stephen Young⁶, Donald U. Stone⁷, David M. Lewis⁶, Lida Radfar⁸, R. Hal Scofield⁴, Kathy Moser Sivils⁹, Harini Bagavant⁹ and Umesh Deshmukh⁹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Virginia, Charlottesville, VA, ³Department of Medicine, University of Virginia, Charlottesville, VA, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose . Autoantibodies reactive with Ro52 are present in almost 70% of Sjögren’s syndrome (SS) patients. This study was undertaken to investigate the role of…
Abstract Number: 149 • 2014 ACR/ARHP Annual Meeting
Automated Digital Analysis of Major Salivary Gland Ultrasound Images
Daniel S. Hammenfors¹, Preben G. Nes², Johan G. Brun¹, Roland Jonsson¹ and Malin V. Jonsson³, ¹Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Sogn and Fjordane University College, Førde, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway
Background/Purpose Primary Sjögren’s syndrome (pSS) is an autoimmune chronic inflammatory disease mainly affecting the salivary and lacrimal glands, with symptoms such as dryness of the…
Abstract Number: 2879 • 2013 ACR/ARHP Annual Meeting
Prognostic Value Of Minor Salivary Gland Assessments In Primary Sjögren’s Syndrome
Anna Risselada¹, A.a. Kruize², J.A.G. van Roon³, F.P.J.G. Lafeber⁴ and J.W.J. Bijlsma⁴, ¹Clinical immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Salivary gland assessment is important for diagnosing primary Sjögren’s syndrome (pSS), as the lymphocytic focus score (LFS) is part of pSS classification criteria. Quantitative…
Abstract Number: 1497 • 2013 ACR/ARHP Annual Meeting
Endosomal TLR Triggering Of B Cells In Sjögren’s Syndrome Induces Increased Plasma Cells Differentiation, Ig Class Switch and Immunoglobulin Production
Marie Wahren-Herlenius¹, Susanna Brauner¹, Marika Kvarnström¹, Lasse Folkersen¹, Sabrina Görgen¹, Christina Trollmo², Vivianne Malmström³ and Gunnel Nordmark⁴, ¹Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Institutet, Stochkolm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Background/Purpose: Patients with primary Sjögren’s syndrome have B cell disturbances resulting in hypergammaglobulinemia and autoantibody production. Most patients are not treated by immunomodulatory drugs, enabling…
Abstract Number: 518 • 2013 ACR/ARHP Annual Meeting
Vitamin D In Sjogren’s Syndrome
Suneet Grewal¹, Judith A. James², R. Hal Scofield³, Kathy L. Sivils⁴, Michael H. Weisman⁵ and Swamy Venuturupalli⁶, ¹Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Cedars-Sinai Medical Center, West Hollywood, CA
Background/Purpose: Unlike other autoimmune diseases in which an association with vitamin D deficiency has been established, the role of vitamin D in Sjogren’s syndrome has…
Abstract Number: 2880 • 2013 ACR/ARHP Annual Meeting
Impact Of Different End Points On The Patient Cohort Size Needed To Demonstrate The Efficacy Of a Therapeutic Intervention In Pss. A Post Hoc Analysis Of The Tears Study (Tolerance and efficacy of Rituximab in primary Sjogren Syndrome study)
Valerie devauchelle-Pensec¹, Sandrine jousse-Joulin², Xavier Mariette³, Jean-Marie Berthelot⁴, Aleth Perdriger⁵, Eric Hachulla⁶, Xavier Puechal⁷, Véronique le Guern⁸, Jean Sibilia⁹, Jacques-Eric Gottenberg¹⁰, Laurent Chiche Sr.¹¹, Vincent Goeb¹², Gilles Hayem¹³, Jacques Morel¹⁴, Charles Zarnitsky¹⁵, Jean Jacques Dubost¹⁶, Jacques-Olivier Pers¹⁷, Divi Cornec¹⁸, Raphaèle Seror¹⁹, Emmanuel Nowak²⁰ and Alain Saraux²¹, ¹Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ²Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ³Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Internal Medicine, Lille CEDEX, France, ⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Internal Medicine, CHU Marseille, Marseille, France, ¹²Rheumatology, Amiens University Hospital, Amiens, France, ¹³Rheumatology Unit, Bichat Hospital, Paris, France, ¹⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ¹⁵Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁶Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ¹⁷Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ¹⁸Department of rheumatology, Brest Occidentale University, Brest, France, ¹⁹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²⁰CIC, CHU Brest, Brest, France, ²¹Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France
Background/Purpose: To calculate the sample sizes needed in future randomized controlled trials (RCTs) testing a therapeutic intervention in pSS, methodologists usually rely on data obtained…
Abstract Number: 1498 • 2013 ACR/ARHP Annual Meeting
Hypofunction In Intact Cell Lobules Reflect Salivary Flow Rates In Sjogren’s Patients
Leyla Y Teos¹, Bill Swaim², Ana Paola Cotrim¹, Margaret Grisius³, Lolita Bebris⁴, Indu Ambudkar⁵, Gabor G. Illei⁶ and Ilias Alevizos⁷, ¹NIDCR, NIH, Bethesda, MD, ²Mptb, NIH/NIDCR, Bethesda, MD, ³NIH, Bethesda, MD, ⁴Sjogren's Clinic, NIDCR/NIH, Bethesda, MD, ⁵Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose: Neurotransmitter stimulation of fluid secretion in salivary glands is regulated by increases in intracellular calcium concentration. The increase in cytosolic calcium triggers ion channel…
Abstract Number: 519 • 2013 ACR/ARHP Annual Meeting
Identification Of IgG4-Related Disease and Analysis Of IgG4 Serum Levels In Different Subgroups Of Patients With Sjögren’s Syndrome
Antónia Szántó¹, Gábor Nagy², Csaba Molnár³ and Margit Zeher¹, ¹Clinical Immunology, University of Debrecen, Medical and Health Science Center, Institute for Medicine, Debrecen, Hungary, ²Regional Immunological Laboratory, University of Debrecen, Medical and Health Science Center, Institute for Medicine, Debrecen, Hungary, ³University of Debrecen, Medical and Health Science Center, Institute for Pathology, Debrecen, Hungary
Background/Purpose: In the clinical diagnostic criteria of IgG4-related disease (IgG4-RD), Sjögren’s syndrome (SS) appears as one of the exclusion criteria. However, in Europe, where Mikulicz’s…
Abstract Number: 2881 • 2013 ACR/ARHP Annual Meeting
Ultrasonographic Salivary Glands Response To Rituximab In Primary Sjögren Syndrome Patients In the Tolerance and Efficacy Of Rituximab In Primary Sjogren Syndrome Study Is Not Associated With The Anatomopathology Changes
Sandrine Jousse-Joulin¹, Valerie Devauchelle-Pensec², Divi Cornec³, Simon Gestin⁴, Luc Bressollette⁵, Thierry Marhadour⁶, Jacques-Olivier Pers⁷, Emmanuel Nowak⁸ and Alain Saraux⁹, ¹Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, ²Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ³Department of rheumatology, Brest Occidentale University, Brest, France, ⁴Vascular medicine, CHU Brest, Brest, France, ⁵Department of ultrasound, Brest Occidentale University, Brest, France, ⁶Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁷Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁸CIC, CHU Brest, Brest, France, ⁹Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France
Background/Purpose: We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Rituximab (RTX) in active pSS patients in France (TEARS study) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].